⏳ Fetching live dividend data...
Home › Calculator › GRTX Dividend Calculator 2026
Galera Therapeutics, Inc. · OTC
Price: $0.10 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in GRTX → $166798809782.01M in 10 years · $13,238,000,776,350,000.00/month
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GRTX position with:
Real after-tax yield depends on where you live and how you hold GRTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2000.00% | 1997.20% | $200,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1700.00% | 1697.20% | $170,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1600.00% | 1597.20% | $160,000 / yr |
| 🇬🇧 UK ISA | 0% | 2000.00% | 1997.20% | $200,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1825.00% | 1822.20% | $182,500 / yr |
| 🇨🇦 TFSA | 0% | 2000.00% | 1997.20% | $200,000 / yr |
| 🇨🇦 CA Taxable | 25% | 1500.00% | 1497.20% | $150,000 / yr |
| 🇦🇺 Super (pension) | 15% | 1700.00% | 1697.20% | $170,000 / yr |
| 🇦🇺 AU Taxable | 30% | 1400.00% | 1397.20% | $140,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1472.50% | 1469.70% | $147,250 / yr |
| 🇫🇷 FR Taxable | 30% | 1400.00% | 1397.20% | $140,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GRTX pays quarterly — 4 times per year. Next ex-div: TBD.
How GRTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GRTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| C-Conversion | 2026-05-15 | 20,813,818 | — | — | ||
| C-Conversion | 2026-05-15 | 20,813.819 | — | — | ||
| Other | 2026-04-07 | 20,813,818.6 | — | — | ||
| C-Conversion | 2026-04-07 | 5,336,870 | — | — | ||
| C-Conversion | 2026-04-07 | 5,336.87 | — | — | ||
| C-Conversion | 2026-04-07 | 1,180,611 | — | — | ||
| C-Conversion | 2026-04-07 | 1,180.611 | — | — | ||
| Sale | 2025-11-20 | 70,000 | $0.02 | $1.4K | ||
| A-Award | 2025-05-01 | 2,000,000 | $0.02 | $44.0K | ||
| A-Award | 2025-05-01 | 6,000,000 | $0.02 | $132.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GRTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →